Compare ZVIA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | FHTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 111.1M |
| IPO Year | 2021 | 2020 |
| Metric | ZVIA | FHTX |
|---|---|---|
| Price | $0.94 | $1.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $3.67 | ★ $4.17 |
| AVG Volume (30 Days) | 451.5K | ★ 685.0K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | 25.32 |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $161,259,000.00 | $30,909,000.00 |
| Revenue This Year | $9.55 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | ★ N/A | $4.14 |
| Revenue Growth | 4.01 | ★ 36.75 |
| 52 Week Low | $0.96 | $1.73 |
| 52 Week High | $2.75 | $7.61 |
| Indicator | ZVIA | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 33.87 |
| Support Level | N/A | N/A |
| Resistance Level | $1.52 | $2.28 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 0.53 | 7.27 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.